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Abstract  
Novel  peptide conjugates of two antitubercular drug candidates were synthesised and characterised  us ing new tufts in 
peptide derivatives (OT14) as carrier moiety. As  antitubercular drug candidates two pyridopyrimidine derivatives, TB803 (2-
a l lylamino-4-oxopyrido[1,2-a]pyrimidine-3-carbaldehyde) and TB820 (4-oxo-2-(pyrrolidin-1-yl )-pyrido[1,2-a]pyrimidin-3-
carbaldehyde) inhibiting vi tal enzyme of Mycobacterium tuberculosis were applied. Membrane affini ty of the compounds  
TB803 and TB820 and their peptide conjugates  was  evaluated us ing experimental  l ipid mono - and bi layer models . 
Penetration ability was assessed tensiometrically from Langmuir monolayer study and applying quartz crystal microbalance 
for the supported l ipid bilayer (SLB) system. Minimal inhibitory concentration (MIC) values remained in a similar micromolar 
range for both of the conjugates  whi le their cel lular uptak e rate was  improved s igni ficantly compared to the drug 
candidates. A correlation was found between membrane affinity properties and results of in vitro biological investigations . 
Analysis of physical/structural properties of SLB in contact with bioactive components and visual ization of the s tructura l  
change by atomic-force microscopy (AFM) provided information on the type and route of molecular interaction of drug 
construction with lipid layers. The possible role of electrostatic interactions between lipid layer and drug candidates  was  
tested in Langmuir-balance experiments using negatively charged l ipid mixture (DPPC+DPPG). Especia l ly the peptide 
conjugates presented increased membrane affinity due to cationic character of the peptide sequence selected for the 
conjugate formation. That is supposed to be one reason for the enhanced cellular uptake observed in vitro for MonoMac6 
cel l  line. The conjugation of antitubercular agents to a peptidic carrier i s  a  promis ing approach to enhance membrane 
affini ty, cel lular uptake rate and in vitro selectivi ty.  
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Introduction 
 
Tuberculosis (TB) is a bacterial infection mainly caused by Mycobacterium tuberculosis (Mtb). 
TB remains a major public health problem worldwide and the first cause of mortality attributable to a 
single intracellular pathogen. Therefore there is an urgent need to develop new agents, active 
against the intracellular bacteria. The cellular uptake of the antituberculotics by infected host cells is 
limited. It is a possible approach to enhance the uptake rate of the antituberculars using peptide 
carriers [1]. The host cell specific delivery of the active compounds could increase the intracellular 
concentration [2]. In this study macrophage – as main host cell –specific conjugates were synthesised 
and characterised [2-6]. 
Tuftsin is a natural tetrapeptide (human: TKPR, canine: TKPK) produced by enzymatic cleavage 
of the Fc-domain of the heavy chain of IgG [4]. Tuftsin activates the immune system, including 
macrophages. C. M. Gupta et al. have developed tuftsin-bearing liposomes that not only enhance the 
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host's resistance against a variety of infections but also serve as useful vehicles for the site -specific 
delivery of drugs in a variety of macrophage-based infections, such as leishmaniasis and TB [7]. A 
group of sequential oligopeptides based on tuftsin has been developed [5]. The synthetic 
oligotuftsins consist of tandem pentapeptide repeat units [TKPKG] n (n: 2, 4, 6, 8) derived from the 
canine tuftsin sequence TKPK extended by a C-terminal Gly [3,5]. The canine tuftsin TKPK, where 
arginine residues is replaced by lysine, that has also basic character has similar biological activities 
like the human tuftsin TKPR [8]. However, the lysine residue in the sequence of TKPK can offer a new 
functional group for connection of a biologically active compound. With the addition of a glycine 
residue to the C-terminal of TKPK racemisation free condensation of the fragments can be achieved 
to form larger oligomers [3]. These compounds are nontoxic, nonimmunogenic, biodegradable, and 
exhibit tuftsin-like biological properties, e.g. immunostimulatory activity and chemotactic activity on 
monocytes. The lysine residues in the sequence of oligotuftsins can offer functional groups for 
connection of a biologically active compound such as antituberculars. New heterotrimer TKPR-
[TKPKG]2 oligotuftsin derivative (OT14) was applied in this study as carrier and targeting moiety.  
Molecular modelling study suggested a flexible structure for oligotuftsins and also demonstrated 
accessibility of the ε-amino group of each lysine residue [3]. In case of OT14 as new carrier Lys8 and 
Lys13 were the most accessible out of the five Lys residues to form chemical linkage with 
antitubercular compound. 
Small molecular drug candidates can be identified using the in silico docking method [9]. With 
this method compounds of a database [10,11], that consists millions of moieties, were docked to the 
dUTPase enzyme (EC 3.6.1.23; Rv2697) [12], which plays a key role in the metabolism of the bacteria. 
dUTPase regulating the extent of uracil incorporation into DNA. Massive uracil incorporation may 
lead to cell death; dUTPase enzyme has therefore been recognized as a high-potential drug target in 
mycobacterial disease control. The efficacy of the compounds with in vitro antitubercular activity can 
be varied by synthetic optimization, so the starting compounds can be converted into drug  
candidates. After structure – activity studies with best ranked heteroaromatic pyrido-pyrimidine 
derivatives on virulent Mtb H37Rv, two of these new optimized antitubercular compounds (TB803, 
TB820 [13]) were conjugated to new oligotuftsin type peptide carrier OT14 through oxime bond.  
To get information whether drugs can get through the barriers in living system such as cell 
membrane or bacterial cell wall is especially important for developments of new drug constructions 
with enhanced efficiency. Simplified lipid model systems were applied to study the details of 
membrane affinity of the bioactive compounds. The Langmuir monolayer of lipid molecules is a 
widely used membrane model due to its well defined and controlled structure as well as versatility in 
composition [12-19]. The molecular interaction with dissolved drug component is monitored by the 
increase of surface pressure allowing to deduce its penetration ability [20-23]. Furthermore, the lipid 
layer can be transferred from the water surface to a solid substrate opening the possible application 
of characterisation techniques of solid surfaces [24-26]. 
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Supported lipid bilayer (SLB) prepared from phospholipid vesicles [27-29] was also used as 
model of cell membranes [30,31]. Once SLBs are constituted on the quartz crystal microbalance 
(QCM) sensor surface the sensitive detection of mass change allows to assess the interfacial 
interactions, the adsorption, desorption processes and membrane integrity [32-34]. With the aid of 
atomic force microscopy the results obtained were related to visual observations of the structural 
change of SLB induced by the interaction with the drug molecules.  
 
In the present work we report on the synthesis of peptide conjugates using new tuftsin type 
carrier peptide and antitubercular drug candidates which were characterised by their membrane 
interaction using mono- and bilayer lipid model systems. Those properties were compared to their in 
vitro behaviour observed in antimicrobial and cytotoxic activity studies as well as the results of 
cellular uptake measurements.  
 
Experimental  
Materials 
1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC, Sigma-Aldrich) was used to form the 
lipid monolayer in the Langmuir trough and create the lipid bilayer on the sensor surface of QCM.  
1,2-Dipalmitoyl-sn-glycero-3-phosphocholine (DPPC, Sigma-Aldrich) and a negatively charged 
lipid, 1,2-dipalmitoyl-sn-glycero-3-phospho-(1’-rac-glycerol) (sodium salt) (DPPG, Sigma-Aldrich) were 
mixed with 1:3 molar ratio and applied as a second model lipid system to mimic a negatively charged 
natural bacterial lipid envelope. 
Chloroform, dichloromethane (purity ≥ 99.8%) and methanol (purity ≥ 99%) were used for 
preparing lipid solution and cleaning the Langmuir trough, all solvents were of analytical grade. 
Doubly distilled water checked by its conductivity (< 5 mS) and surface tension (72.0 mN/m at 
(25 ± 0.5) °C) was used for buffer preparation and it was the subphase in the Langmuir balance 
measurements.  
A buffer consisting of 10 mM Tris, 150 mM NaCl and 2 mM CaCl2 at pH = 7.4 (Sigma-Aldrich) was used 
for QCM measurements and liposome preparation. 
For vesicle preparation, 10 mg POPC powder was first dissolved in 1 mL mixture of chloroform 
and 5% (V/V) methanol in a glass flask. After 30 min mixing, the organic solvents were evaporated 
using a rotary evaporator and dried with a vacuum pump for two hours to remove any residual 
solvents. The dried lipid film was then rehydrated with 10 mL buffer. To prepare unilamellar vesicles, 
the stock (1.0 g/L) and diluted (0.1 g/L) lipid suspensions were forced through a polycarbonate 
membrane filter with 100 nm pore size for 31 times each at 30 °C using an Avanti Mini-Extruder 
(Avanti Polar Lipids, USA) directly before QCM measurements. The hydrodynamic diameter of these 
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particles is (104 ± 7) nm which was determined by dynamic light scattering measurements 
(Brookhaven, BI-200SM goniometer system, BI-9000AT digital correlator, Coherent Genesis MX488-
1000STM laser-diode system operating at 488 nm wavelength and emitting vertically polarized light).  
For solid phase peptide synthesis, analysis and purification commercial grade reagents were 
used without further purification. All amino acid derivatives and resins were purchased from Iris 
Biotech GmBH (Marktredwitz, Germany). Coupling agents, cleavage reagents and scavengers (1-
hydroxybenzotriazole hydrate (HOBt), N,N′-diisopropylcarbodiimide (DIC), piperidine, 1,8-
diazabicyclo[5.4.0]undec-7-ene (DBU), trifluoroacetic acid (TFA), triisopropylsilane (TIS) were 
obtained from Sigma-Aldrich. 1-Methyl-2-pyrrolidon was obtained from Merck Hungary. N,N-
Dimethylformamide (DMF), dichloromethane (DCM), diethylether and dimethylsulfoxide (DMSO) 
were purchased from Molar Chemicals Ltd (Hungary). Hydrochloric acid (HCl), acetic acid (CH3COOH), 
solvent for HPLC (acetonitrile (ACN)) were purchased from Sigma-Aldrich.  
TB803 (2-allylamino-4-oxopyrido[1,2-a]pyrimidine-3-carbaldehyde) and TB820 (4-oxo-2-
(pyrrolidin-1-yl)-pyrido[1,2-a]pyrimidin-3-carbaldehyde) were provided by Ubichem Pharma Services 
(Hungary). 
For the in vitro studies (cellular uptake, MTT assay) RPMI-1640 medium, gentamicin and 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) were obtained from Sigma-Aldrich. 
Dimethyl sulfoxide (DMSO) was purchased from Merck Hungary. Fetal calf serum (FCS) was 
purchased from Biocenter Ltd (Hungary). Phosphate buffered saline (0.01 M PBS, pH = 7.4) was 
prepared by dissolving 150 mmol NaCl, 8 mmol Na2HPO4·2H2O, 2.7 mmol KCl and 15 mmol KH2PO4 
(products of Sigma-Aldrich) in 1000 mL of deionized water. 24-well and 96-well flat-bottomed plates 
were the products of Sarstedt Ltd (Hungary). 
 
Synthesis of the peptide conjugates 
The TKPR[TKPKG]2 (OT14) new heterotrimer analogue of the tuftsin sequence was produced 
on Fmoc-Rink Amide MBHA resin in an automated peptide synthesiser (Syro-I, Biotage, Sweden) 
using Fmoc/tBu strategy.  
TB803 and TB820 compounds were conjugated to the OT14 peptide via oxime ligation. The N ε-
4-methyltrityl protecting groups of the side chain of two Lys residues were selectively removed with 
2% TFA, 2% TIS in DCM (6 × 5 min). After the 4-methyltrityl protecting group removal the resin was 
washed (5 × 1 min DCM) and neutralised (5 x 1 min 10% DIEA in DCM) and free amino groups were 
reacted with Boc-aminooxyacetic acid. After peptide was removed from the resin with TFA in the 
presence of scavengers (cleavage mixture: 95% TFA, 2.5% TIS, 2.5% H2O), aminooxy-peptide was 
allowed to react with the TB803 or TB820 aldehyde compounds in solution (2.2 equivalent TB803 or 
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TB820 was added to the peptide in 0.2 M NaOAc/AcOH buffer, pH = 5.0 and DMF 1:1 V/V, the 
reaction was stirred at room temperature for 16 hours).  
 
 
Reverse Phase High-Performance Liquid Chromatography (RP-HPLC) 
The conjugates were purified on a KNAUER 2501 HPLC system (KNAUER, Germany) using a 
semipreparative Phenomenex Jupiter C18 column (250 mm × 10 mm) with 10 μm silica (300 Å pore 
size, Gen-Lab Ltd., Hungary). Linear gradient elution (0-5 min 10% B, 5-75 min 10-80% B) with eluent 
A (0.1% TFA in water) and eluent B (0.1% TFA in acetonitrile/H2O (80:20, V/V)) was used at a flow 
rate of 4 mL/min. Peaks were detected at 220 nm. Analytical RP-HPLC was performed on an 
Exformma EX1600 HPLC system (Gen-Lab Ltd., Hungary) using an Agilent Zorbax SB-C18 column 
(150 mm × 4.6 mm) with 5 μm silica, 100 Å pore size (Kromat Ltd, Hungary) as a stationary phase. 
Linear gradient elution (0-10 min 0% B, 10-30 min 0-90% B) was used at a flow rate of 1 mL/min. 
Peaks were detected at 220 nm. 
 
Mass Spectrometry (MS) 
Electrospray (ESI)-mass spectrometric analysis were carried out on an Esquire 3000+ ion trap 
mass spectrometer (Bruker Daltonics, Germany). Spectra were acquired in the 50 - 2500 m/z range. 
Samples were dissolved in a mixture of 0.1% acetic acid in acetonitrile/H2O (50:50, V/V) (Fig. 1, 
Table 2). 
 
Monolayer studies 
The lipid layer measurements were accomplished by a computer controlled KSV MiniMicro 
Langmuir balance (KSV Instruments, Finland). The trough was mounted on an aluminium base with 
built-in channels for temperature control of the subphase and enclosed in an environment chamber. 
The trough was made of Teflon and the barrier from polyoxymethylene (POM). The  experiments 
were performed at (25 ± 0.5) °C. 
Lipids were dissolved in chloroform, and 50 µL of 0.2 g/L solutions were applied by a 
microsyringe to form monolayer on the water surface. The solvent was allowed to evaporate for 
15 min. By two movable barriers the lipid layer was compressed into a dense and symmetric 
monolayer while the surface pressure and the area were continuously recorded. The su rface 
pressure was measured by the Wilhelmy method using a chromatography paper sensor (Whatman 
Chr1).  
The lipid monolayer was compressed to a given surface pressure (20 mN/m) for penetration 
experiments. Drugs and drug-conjugates were dissolved in water and were injected below the 
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compressed lipid monolayer at a fixed barrier position to attain a final concentration of 2 µM in the 
subphase. The change in surface pressure as the indicator of drug penetration was recorded for 1 h. 
The degree of penetration was given as the average of two independent measurements with a 
deviation < 0.5 mN/m. 
 
Bilayer studies 
QCM (Quartz Crystal Microbalance) measurements 
A QCM200 (Stanford Research Systems, USA) system was used to create lipid bilayer on SiO 2 
coated quartz crystal (5 MHz AT-cut) and study the interactions with drug candidates and their 
peptide-conjugates. The equipment includes a flow-through cell, an oscillator and an analyser. The 
flow cell was connected to a peristaltic pump applying a flow rate of 0.2 mL/min. Experiments were 
performed at (25 ± 0.1) °C. After achieving a stable baseline with continuous flow of the buffer in the 
liquid flow cell, 1 mL freshly prepared POPC liposome system with a concentration of 0.1 g/L was 
injected. Following the formation of lipid bilayer and washing with buffer 1 mL drug solution was 
injected. The peristaltic pump was switched off for an hour so that interactions between the bilayer  
and the drug molecules can take place. Finally the system was washed with buffer. During 
measurements the resonance frequency (f) and motional resistance (R) of the sensor crystal were 
recorded. 
The adsorbed mass (Δm) on the sensor surface can be related to changes in resonance 
frequency (Δf) through the Sauerbrey equation [35]:  
 mCf  f  (1) 
where Cf corresponds to the sensitivity factor for the crystal (56.6 Hz × µg
-1 × cm2 for a 5 MHz AT-cut 
quartz crystal at room temperature). Measurements were done in triplicates.  
 
AFM (Atomic Force Microscopy) measurement 
Sensor surfaces were investigated by atomic force microscopy (AFM) (Park System, XE-100, 
South Korea) after QCM measurements to visualize changes in the structure of the lipid membrane 
following their interaction with the drug candidates. Measurements were performed in air at 25 °C in 
non-contact mode. The cantilever (NSC15/AlBS, MicroMasch, force constant 40 N/m, 325 kHz 
resonance frequency) made of Si3N4 has a tip curvature radius less than 10 nm with an Al-coated 
reflective back side. A scanning rate of 1.0 Hz was used with a scan window of 5 × 5 µm2. The images 
were analysed using the XEI 1.8 program (Park Systems, South Korea) to obtain information on the 
lipid bilayer and the effect of the interactions with peptides and conjugates.  
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Evaluation of in vitro antimycobacterial activity on Mycobacterium tuberculosis H37Rv 
In vitro antimycobacterial activity of the compounds was determined on M. tuberculosis H37Rv 
(ATCC 27294) by serial dilution method in Sula semisynthetic medium [36], which was prepared in-
house (pH = 6.5). Compounds were added to the medium as DMSO solutions at 10 various doses 
(range of final concentration was between 0.5 and 100 μg/mL). Minimal inhibitory concentration 
(MIC) was determined after incubation at 37 °C for 28 days. MIC was the lowest concentration of a 
compound at which the visible inhibition of the growth of M. tuberculosis H37Rv occurred. In order to 
confirm growth inhibition, colony forming unit (CFU) was determined by subculturing from the Sula 
medium onto drug-free Löwenstein−Jensen solid [37] medium Samples were incubated for 28 days. 
Experiments were repeated at least two times [2,5,12,13,38,39]. All experiments with virulent human 
pathogen M. tuberculosis H37Rv were carried out in a bio-safety level 3 (BL-3) containment area at 
Korányi National Tuberculosis Hospital (Budapest, Hungary).  
 
Determination of in vitro cytotoxic activity on MonoMac6 cells 
MonoMac6 cell cultures (DSMZ no.: ACC 124, Deutsche Sammlung von Mikroorganismen and 
Zellkulturen GmbH, Braunschweig, Germany) were maintained in RPMI-1640 medium containing 10% 
FCS, 2 mM L-glutamine, and 160 μg/mL gentamycin at 37 °C in 5% CO2 atmosphere. The cells were 
plated on 96-well plates (104 cells/100 μL medium/well) and after 24 h incubation at 37 °C, cells were 
treated for 16 h (overnight, ON) with the compounds dissolved in serum free RPMI-1640 medium 
(cDMSO = 1.0%, V/V) at 5 × 10
-2 to 5 × 102 µM concentration range. Control cells were treated with 
serum free medium only or with DMSO containing serum free medium (c = 1.0%, V/V) at 37 °C. After 
the treatment and incubation, cells were washed twice with serum-free medium (centrifugation: 
1000 rpm, 5 min) and the cell viability was determined with (4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT)-assay [40-42]. 45 μL MTT solution (2 mg/mL) was added to each 
well and during 3.5 h incubation purple crystals were formed by mitochondrial dehydrogenase 
enzyme present in the living cells. After incubation cells were centrifuged for 5 min at 2000 rpm and 
the supernatant was removed. Crystals were dissolved in DMSO and the optical density (OD) of the 
samples was determined at λ = 540 and 620 nm using an ELISA Reader (Labsystems MS reader, 
Helsinki, Finland). OD620 was subtracted from OD540. The percent of cytotoxicity was calculated 
using the following equation: cytotoxicity (%) = 100 × (1-ODtreated/ODcontrol), where ODtreated and 
ODcontrol correspond to the optical densities of treated and control cells, respectively. Cytotoxicity  (%) 
was plotted as a function of concentration, fitted to a sigmoidal curve and the 50% inhibitory 
concentration (IC50) value was determined from these curves. Each experiment was repeated at least 
2 times and the average IC50 values were presented. The curves were defined using Microcal Origin 
7.5 software. 
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Determination of in vitro cellular uptake profiles of the compounds by flow cytometry 
The measurements of the cellular uptake of the compounds were evaluated by flow cytometry 
(BD LSR II, BD Biosciences, USA) on MonoMac6 human monocytic cell line. Cells were harvested in 
the logarithmic phase of growth and plated on a 24-well tissue culture plate (105 cells/1 mL 
medium/well) 24 h prior to the experiment. Compounds were dissolved in serum free RPMI-1640 
medium, and running dilutions were prepared. The highest concentration of the compounds on the 
cells was 250 μM. Cells were incubated with compounds TB820, TB803, TB820−OT14, TB803-OT14 
for 60 min (37 °C, 5% CO2 atmosphere). After centrifugation (1000 rpm, 5 min, 4 °C), the supernatant 
was removed, and 100 μL of 1 mM trypsin was added to the cells. The effect of trypsin was stopped 
by 900 µL Hepes buffer HPMI (HPMI; 100 mM NaCl, 5.4 mM KCl, 0.4 mM MgCl2, 0.04 mM CaCl2, 
10 mM Hepes, 20 mM glucose, 24 mM NaHCO3 and 5 mM Na2HPO4 at pH = 7.4 [43] containing 10% 
FCS, and the cells were transferred from the plate to FACS-tubes. Cells were centrifuged (1000 rpm, 
5 min, 4 °C) and the supernatant was removed. After this procedure, cells were resuspended in 
500 µL HPMI, and the intracellular fluorescence intensity of MonoMac6 cells was monitored (488 nm 
(Coherent Sapphire, 22 mW) laser, channel PE LP550 (emission at λ = 550 nm)) which is proportional 
to the cellular uptake. Data were analysed with FACSDiVa 5.0 software. All measurements were 
performed in duplicate. The graph was generated using Prism (version 5) software.  
 
 
Results and Discussions 
 
New pyridopyrimidine derivatives were defined using in silico docking method [44] prior to 
chemical optimization based on structure – activity studies [31,45]. The in vitro antimycobacterial 
activity of the compounds was characterised by the determination of the minimal inhibitory 
concentration (MIC) on M. tuberculosis H37Rv culture with 4-week exposure period [2]. For further 
chemical modification a pyrido-pyrimidine derivative (2-allylamino-3-allyliminomethylpyrido[1,2-
a]pyrimidin-4-one) was chosen. After structure – activity studies with pyrido-pyrimidines two of 
these new optimized antitubercular compounds (TB803, TB820 [13]) were conjugated to a new 
oligotuftsin derivative heterotimer peptide carrier OT14 through oxime bond (Fig. 1). We observed 
that the Lys8 and Lys13 residues were the most accessible out of the five Lys residues of OT14 carrier 
to form chemical linkage with antitubercular compound.  
TB803-OT14 and TB820-OT14 conjugates were carefully characterised by mass spectrometry, 
analytical RP-HPLC and amino acid analysis (data not shown). The compounds exhibited fluorescence 
when excited at 488 nm enabling their detection in cellular uptake measurements (emission at 
λ = 550 nm) without additional labelling.  
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Fig. 1. Chemical structure of TB803, TB820 compounds, their peptide conjugates, and ESI -MS mass 
spectra of the conjugates. TB803 and TB820 compounds were conjugated to the peptide carriers via 
oxime ligation.  
 
Monolayer studies 
 
The membrane affinity of the drug candidates and conjugates was studied in Langmuir-balance 
experiments, where the adsorption and/or penetration into the lipid layer were detected. POPC and 
DPPC+DPPG mixture as characteristic components of eukaryotic cell membrane or bacterial cell 
envelope were chosen to form the lipid monolayers as membrane model.  
Surface pressure – area isotherms were recorded for the lipid monolayer systems. The 
isotherm of POPC shows a gradual change with molecular area and does not present the phase 
transition typical for DPPC. This shape in connection with the low phase transition temperature 
(-2 °C) of POPC is in agreement with the previously published results [46,47]. The DPPC+DPPG 
mixture conversely shows the distinct states of lipid monolayer characteristic for pure DPPC. The 
presence of 25 mol% of the anionic DPPG has negligible effect on the phase behaviour of the lipid 
film however, could greatly influence the interaction with cationic peptides [48].  
Surface pressure of 20 mN/m was selected as starting value of the compressed lipid film for 
the penetration experiments which is high enough to represent the packing of lipid molecules in the 
membrane and appropriate value to allow evaluation of the possible differences in the penetration 
ability of the various components studied. 
Increase of surface pressure () was detected as function of the time following the 
introduction of drug compound into the subphase of lipid monolayer. In the first period after 
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injection a fast increase of the surface pressure was observed. After approximately 5 min the change 
of surface pressure became smaller. Δ values determined at t = 1 h characterising the penetration 
ability of the drugs are summarized in Table 1.  
 
Table 1. Penetration (Δ) of drug candidates into lipid monolayer determined in Langmuir balance 
experiments as well as frequency (f) and resistance (R) in stage 5 at concentration of 430 μM 
determined in QCM measurements. σM values are the standard error of the mean of three replicate 
measurements. 
 
 Penetration measurements QCM measurements 
 Δ  (mN/m)  
Drug POPC σM 
DPPC+
DPPG 
σM Δf5/Hz σM ΔR5/ Ω σM 
Δf5,m / 
Hz 
TB803 1.0 0.2 0.4 0.2 1.0 0.3 0.0 0.3 1.0 
TB803-
OT14 
2.7 0.2 5.6 0.2 -4.0 0.6 0.8 0.1 -2.6 
TB820 0.8 0.2 1.4 0.2 2.2 0.4 0.2 0.1 2.6 
TB820-
OT14 
1.8 0.3 4.8 0.3 -0.8 0.4 1.6 0.2 2.2 
 
 
Small drug molecules just slightly penetrate into the lipid monolayers. The penetration affinity 
is significantly increased for the peptide conjugates (TB803-OT14, TB820-OT14), especially when 
electrostatic interactions with the charged DPPC+DPPG monolayer are effective. The highest 
membrane affinity was obtained for the TB803-OT14 considering any of the lipid layers. 
 
Bilayer studies 
 
The membrane affinity of the drug candidates and their peptide conjugates were characterised 
by their interaction with supported lipid bilayers. QCM-R technique was employed to follow the 
interactions at the SLB - liquid interface. The supported bilayers were prepared in situ in the QCM 
liquid cell by spreading POPC liposomes on silica coated QCM sensor crystals. Mass changes were 
detected as changes in the resonance frequency of the sensor quartz crystal. The increased mass of 
the sensor leads to the decrease of vibrational frequency. In addition to that the QCM-R technique 
allows for the simultaneous and independent determination of the motional resistance of the sensor 
which can be used to interpret changes in the structure of the liquid-solid interface. Fig. 2 shows a 
typical measurement curve. Following the stable baseline (1) liposomes were introduced (2) and 
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after spreading and rupture of liposomes a lipid bilayer was formed (3). Then the bioactive 
compound was injected and Δf and ΔR showed the interaction of drug or drug-conjugate with lipid 
bilayer (4) followed by a rinsing with buffer (5). 
 
Fig. 2. Changes in the resonance frequency (Δf, solid line) and the motional resistance (ΔR, dashed 
line) of the QCM sensor crystal over time. The measurements could be divided into sequences: 1: 
buffer baseline with bare silica surface; 2: introduction of liposome, spreading, formation of lipid 
bilayer; 3: buffer baseline with lipid bilayer; 4: addition of drug candidate solution, interaction w ith 
lipid layer; 5: washing with buffer. 
 
Fig. 3. Frequency change (Δf5) at the end of section 5 in the QCM experiment indicating interaction of 
TB803 (Δ), TB820 ( ) and their peptide conjugates (closed symbols) with POPC bilayer as a function 
of concentration. Error bars represent the standard error of the mean of three replicate 
measurements. 
 
Frequency change characterising the interaction with SLB can be seen as a function of 
concentration in Fig. 3. Behaviour of TB803 and TB820 show relevant difference from their 
conjugates. The values of the two drug candidates follow the same trend indicating slight mass 
reduction during the interaction. (TB803 cannot be measured at higher concentrations due to its 
limited solubility.) On the other hand the conjugates differ also from each other. The frequency 
values for TB803-OT14 significantly decrease with increasing concentration which is not the case for 
TB820-OT14. The interaction of TB803-OT14 with lipid bilayer suggests a clear affinity resulting in 
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mass increase of the surface layer. The behaviour of the TB820-OT14 is different in both the degree 
and sign of frequency change. 
Frequency and resistance changes relevant for the interaction were determined relative to the 
values corresponding to the intact lipid bilayer (stage 3). Δf5 and ΔR5 are the values after 15 min 
washing with buffer following the 40 min contact with the drug solution. The results for the cases of 
the drug concentration of 430 μM are collected in Table 1. 
For the more detailed interpretation of the data and to get information on the possible 
structural changes in the surface layer it should be considered that the changes in the resonance 
frequency consist of two contributions. One is the change in mass on the sensor surface; the other is 
from the changes in the viscoelastic properties of the liquid phase near the surface. If the viscosity 
and density of the liquid medium remain constant during the measurement, the viscous loading of 
the sensor can still change due to the formation of non rigid layers. This means that measuring only 
the frequency in liquid it is not possible to differentiate between mass changes and structural 
changes of the interface. The independent measurement of the motional resistance provides a way 
to detect sensitively changes in the viscoelastic properties of the surface layer. Using the 
Butterworth-Van Dyke equivalent circuit model a linear relationship can be derived between the 
changes in the motional resistance and the density-viscosity (𝜌𝐿𝜂𝐿)
1/2 of the surface layer [49] 
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where n is the number of sides in contact with liquid, ω is the angular frequency at resonance, L is 
the inductance of the unperturbed resonator, ρq and μq are the density and shear modulus of quartz. 
Similarly the effect of viscous loading on the resonance frequency can be estimated using Kanazawa-
Gordon equation [50,51] 
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where f0 is the resonance frequency of the unloaded crystal.  
Considering that the motional resistance is mainly affected by the changes in the viscoelastic 
properties of the surface layer while mass changes also add to the measured frequency changes, 
these two equations can be used to estimate the viscous loading contribution in the total frequency. 
First   2/1LL  is calculated using Eq. 2 followed by the estimation of the Δf due to changes in the 
sensor surface structure and/or environment using Eq. 3. Subtracting this contribution from the total 
frequency change the mass change contribution of the frequency (Δf5,m) can be calculated. These 
calculated values are also presented in Table 1. 
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Increased resistance value is the signal of the expansion of the surface layer, which becomes 
looser. Accordingly, a decrease in the motional resistance indicates the layer becoming denser, more 
rigid. 
For the various drug candidates a definite distinction can be made based on the exhibited 
motional resistance changes depending on the structure of the molecules. For the small drug 
candidates the change in motional resistance is close to zero indicating no significant variation in the 
viscous property of the layer. The peptide conjugates of the two drug molecules however, present 
marked increase of motional resistance. That can be considered as the viscoelastic changes at the 
interface due to the interaction with SLB, especially for TB803-OT14. Considering these results the 
peptide conjugates are able to loosen the lipid bilayer increasing the viscosity of the surface layer.  
Simultaneously, the calculated components of the frequency change responsible for mass 
change (∆f5,m) are positive except for the case of TB803-OT14. That small mass reduction indicates 
that the molecules interact slightly with the lipid membrane, a partial displacement of SLB can occur.  
On the contrary ∆f5,m is a negative value indicating mass increase for drug conjugate  TB803-
OT14. This strong attraction is in accordance with the highest membrane affinity of that conjugate 
obtained in lipid monolayer experiment.  
Morphology studies of the lipid layers using AFM could help to understand the changes 
observed during the QCM measurements. Representative AFM topography images of the different 
systems are shown in Fig. 4. 
AFM studies confirm that the lipid membranes remain almost intact following the interaction 
with TB820 (Fig. 4. B) and TB803, only small increase in surface roughness could be observed when 
comparing pictures with those of pure POPC membrane (Fig. 4. A). That can be related to the limited 
disturbance of SLB by the slight interaction.  
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Fig. 4. AFM topographic images of pure POPC membrane (A), POPC membrane after interaction with 
small molecule TB820 (B) and peptide conjugates TB803-OT14 (C) and TB820-OT14 (D) with cross 
section profiles. Scale bar represents 1 µm. 
 
AFM image of the lipid layer following interaction with the TB803-conjugate revealed that only 
an increase in surface roughness can be detected along with some small sized (5-10 nm high) 
aggregates (Fig. 4. C). This is consistent with the QCM results where a significant drop in resonant 
frequency corresponds with the addition of mass onto the lipid layer.  
In the case of TB820-OT14 a considerably different morphology was observed. Although there 
are only small mass changes during the binding process the structure of lipid bilayer is drastically 
changed. This is visualized in AFM in Fig. 4. D. The uniform bilayer structure is destroyed. The main 
feature of these images is the presence of large aggregates while parts of the bilayer are still 
observable. If we calculate the total volume of these aggregates it turns out to be the same volume 
as a continuous POPC bilayer would have. For multiple images this turned out to be consistent within 
5% error. This interfacial restructuring is upheld by the QCM results. The presence of the loose 
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aggregates would lead to an increase in the viscous loading as observed while  most of the material 
remained on the surface. 
The difference in the behaviour of the two conjugates could be attributed to the structure of 
the small molecules. TB803 with its allylamine group would have a smaller surface area than TB820 
with the pyrrolidine group. This could be the reason for the effect TB820-conjugate had on the POPC 
membrane. Due to its larger surface area the insertion of the molecule would lead to a more 
disrupted membrane leading to the eventual destruction of the bilayer structure.   
 
In conclusion two main effects can be distinguished considering the influence of drug 
interacting with lipid layers (Fig. 5). In the case of the small molecules a weak interaction is proposed, 
supported by their low membrane affinity. The presence of the molecules at the interface disturbs 
the ordered structure of the membrane in some extent which might lead to a loss of small  fraction of 
membrane lipids. In the second case with the peptide conjugates the peptide chains bind to the lipid 
membrane via electrostatic interactions, disturbing the well ordered membrane structure. The 
hydrophobic drug parts of the molecules can then penetrate more easily the membrane. Depending 
on the size of the small molecular drug part the conjugates either disturb or completely destroy the 
lipid bilayer structure.  
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Fig. 5. Possible mode of interaction between lipid bilayers and TB803, TB820 (A) and their peptide 
conjugates (B). 
 
 
In vitro bioactivity studies 
Minimal inhibitory concentration (MIC) values of the compounds on M. tuberculosis H37Rv 
Minimal inhibitory concentration (MIC) of the conjugates, the carrier peptide and the free 
antituberculars TB803 and TB820 were studied on M. tuberculosis H37Rv, which is a human pathogen 
responsible for the infectious disease of tuberculosis. TB803 and TB820 compounds have outstanding 
inhibitory effect on the bacterial culture. The TB803-OT14 conjugate exhibited uniquely good activity, 
but TB820-OT14 effect was excellent. The carrier peptide itself was not effective on bacterial culture.  
We observed that the antitubercular activity of the free TB803 and TB820 was essentially preserved 
after conjugation to peptide carriers through oxime bond (Table 2). These results suggested the 
significant in vitro antimycobacterial effect of the compounds remained attractive in the conjugate.  
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Table 2 
Characteristics of the compounds. 
 
Compound M
 a
 
Rt b 
(min) 
MIC c 
(μM) 
IC50 
d 
(μM) 
Selectivity 
index e 
TB803 229.2 24.5 4 >500 >125 
TB803-OT14 2091.8 21.4 38 >500 >13 
TB820 243.3 23.0 4 >500 >125 
TB820-OT14 2151.5 21.2 9 >500 >56 
a
 Measured molecular mass by Bruker Esquire 3000+ ESI -MS. 
b
 Retention time on analytical RP-HPLC  
c
 Minimal inhibitory concentration on Mycobacterium tuberculosis H37Rv strain determined in Sula media  
d 
IC50: concentration of peptide providing 50% cytotoxicity of MonoMac6 cells in RPMI -1640 media. 
e 
Selectivity index was calculated from IC50/MIC (for samples, where IC50 was higher than 500 μM, a value 
of 500 μM was assigned to calculate selectivity index). 
 
In vitro cytotoxicity on human MonoMac-6 cells 
Determination of the in vitro cytotoxic effect of the compounds was carried out on human 
monocytic cell line MonoMac6 using MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) assay. The IC50 values (the concentration which decreases the viability of the cells to 50% 
from the maximal viability) were determined from the dose-response curves (Table 2). The 
MonoMac6 cells are considered as an in vitro model of the host cell macrophages. The selectivity 
indexes (SI) related to each bacterial strain were determined as a ratio of the IC50 value for cytotoxic 
activity to the MIC value (Table 2). The compounds did not influence the cell viability up to 500 μM 
concentration and they showed good selectivity due to the cytotoxicity (low IC 50 value) on human 
MonoMac-6 cells (Table 2). 
 
In vitro cellular uptake profile of the compounds 
The cellular uptake of the free TB803, TB820 and their peptide-conjugates was determined by 
flow cytometry on MonoMac6 human monocytic cell culture. MonoMac6 cells are phagocytic and 
were established as a cell line, which appears to have phenotypic and functional characteristics of 
mature blood monocytes. MonoMac-6 line is frequently used as a host cell model for intracellular 
bacteria such as M. tuberculosis. Small molecular weight organic compounds such as the new 
antitubercular candidates and cationic peptides are known to bind to the outside of the cell 
membrane and can thereby give false positive fluorescence signals, as fluorescence analysis cannot 
discriminate between internalized or surface bound compounds. Protocols to reduce fluorescence 
signals from surface bound compounds include treating cells with trypsin. Prior to flow cytometry 
measurements the MonoMac-6 cells were trypsinised to reduce the surface structure of the cells by 
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its proteolytic action in order to remove the aspecifically bound and not intracellular fluorescent 
compounds and peptide conjugates [52-54]. 
All compounds, TB803 and its conjugate are fluorescent. Minimal internalization was detected 
for TB803 and TB820 compare to that of the untreated control (Fig. 6). Conjugation to OT14 peptide 
significantly increased cellular uptake of the compounds,  the treatment with the conjugates has 
resulted in the highest intracellular fluorescence intensity of MonoMac-6 cells. Enhanced cellular 
uptake was performed by conjugation of new in silico identified drug candidates to OT14 tuftsin 
derivative. 
 
 
Fig. 6. Cellular uptake of the TB803, TB820 and their OT14 conjugates in 250 µM concentration by 
MonoMac6 human monocytic cells.  
 
 
Conclusions 
 
Using in silico docking approach the M. tuberculosis dUTPase enzyme has resulted in a new 
antimycobacterial compound family (TB8). Considering MIC values and chemical structure, two 
moieties were chosen from this compound family for conjugation to a new heterotrimer OT14 
oligotuftsin carrier. Efficient synthetic pathway was applied to conjugate the TB803 and TB820 
compounds to peptidic carriers via oxime linkage. The new antitubercular drug candidates and their 
peptide conjugates were studied for in vitro activity and membrane affinity.  
TB803 and TB820 show little membrane affinity in lipid mono- and bilayer models. The 
evaluation and comparison of the results of the QCM and AFM measurements can give further 
information to reveal what happens during the interaction between the lipid bilayer and the 
candidate. The frequency and the resistance changes indicate that the small molecules interact only 
slightly with the lipid membrane which is in accordance with their low penetration into lipid 
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monolayer. Conjugating the drug candidates to OT14 oligotuftsin changed their behaviour 
dramatically. Enhanced membrane affinity was found in the monolayer studies that increased further 
when negatively charged DPPC+DPPG lipid mixture was used as model membrane. This indicates that 
electrostatic interactions play an important role especially in the presence of cationic peptide 
sequence in the conjugate. A combination of QCM and AFM studies on SLB model showed the strong 
interaction of drug-peptide conjugates inducing drastic structural changes in the lipid bilayer. 
Bioactivity of the compounds was investigated in vitro. All  compounds have outstanding 
inhibitory effect on the M. tuberculosis bacterial culture. For the effective treatment of the 
tuberculosis it is essential for drug candidates to be able to kill intercellular bacteria. Therefore 
cellular uptake measurements were also performed. The treatment of MonoMac6 cells with the 
TB803 and TB820 compounds evoked almost the same intracellular fluorescent intensity as that of 
the untreated control, which means that the uptake rate of the free drug candidates were limited. In 
contrast, the mean fluorescent intensity was significantly higher after the incubation with the OT14 
conjugates. Coupling the compounds to OT14 peptide has resulted in non cytotoxic conjugates, and 
the intracellular fluorescent intensity of TB803−OT14 and TB820-OT14 conjugates treated cells was 
higher than that of TB803 and TB820 treated cells. These results are in good correlation with the 
outcome of the model membrane studies.  
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